The US Food and Drug Administration (FDA) recently approved a new drug called LEQEMBI to treat this disease. This drug is known as the first drug that is effective in slowing down the progress of dementia in the early stages of Alzheimer’s.
According to Tekna Technology Media Medical and Health News Service, Alzheimer’s is a progressive brain disease that gradually affects a person’s memory, language and thinking abilities. Unfortunately, there is still no definitive treatment for this disease, but early diagnosis and treatment can significantly slow down the disease process.
Early signs of Alzheimer’s may include frequent forgetting of names, words or recent events, repeating questions continuously, losing things and being unable to find them.
Early diagnosis of Alzheimer’s is very important because it allows the doctor to start the appropriate treatment and help the patient and his family to plan for the future. Available treatments can help improve patients’ quality of life and reduce disease progression. To diagnose Alzheimer’s, your doctor may use a variety of methods, including a physical exam, blood tests, brain imaging (such as MRI or PET), and cognitive assessments.
LEQEMBI is prescribed to treat people who are in the early stages of Alzheimer’s and have mild cognitive impairment or mild dementia. For more information about this drug, you can visit its official website. With recent advances in Alzheimer’s diagnosis and treatment, we hope that this disease can be completely cured in the near future. Until then, early diagnosis and appropriate treatment can help patients and their families cope better with this complex disease. To see the latest news, refer to the scientific news page of Tekna Media.
RCO NEWS